Tuesday, January 30, 2018 10:15 PM ET
Significant Insider Selling Continues at Intellia Therapeutics (NTLA)
There was a notable sale of shares of Intellia Therapeutics by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Caribou Biosciences Inc, 10% Owner — sold 550,645 shares in the company having a market value of approximately $14,746,273. There have been 2 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 1,859,783 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 2,410,428 shares and have averaged 803,476 shares per transaction over this time period.
The number of insider buy/sell trades at Intellia Therapeutics is above the 191 peer company average over the last 90-day period. The Biotechnology & Medical Research peer group saw 168 buy/sell trades during this period for an average of 0.9 transactions per company. The number of shares per buy/sell trade for Intellia Therapeutics insiders was also higher. Within the peer group there were 11,346,492 shares purchased and 12,354,260 shares sold with company insiders disposing of 5,999 shares on average.
In order to focus on significant insider buying and selling activity, all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers has been eliminated data obtained to evaluate and write this story.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2018 UpTick Data Technologies. All rights reserved.